28
Participants
Start Date
December 11, 2019
Primary Completion Date
October 31, 2020
Study Completion Date
October 31, 2020
CTI-1601
CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
Placebo
Placebo Comparator
Clinilabs Drug Development Corporation, Eatontown
Lead Sponsor
Collaborators (1)
Veristat, Inc.
OTHER
Metrum Research Group, LLC
UNKNOWN
Larimar Therapeutics, Inc.
INDUSTRY